Table 3.
Vaccination status of students participating in COVID-19 serology investigation — fall academic semester 2021, Wisconsin
| September | December | |||
|---|---|---|---|---|
| Total participants | 223 | 100% | 172 | 100% |
| Status, No. (%)a | ||||
| Unvaccinated | 12 | 5.4% | 10 | 5.8% |
| Partially vaccinated | 5 | 2.2% | 4 | 2.3% |
| Fully vaccinated | 203 | 91.0% | 109 | 63.4% |
| Boosted | 3 | 1.3% | 49 | 28.5% |
| Primary series received, No. (%) | ||||
| CoviShield (AstraZeneca) | 3 | 1.3% | 5 | 2.9% |
| Covaxin | 0 | -- | 2 | 1.2% |
| Johnson & Johnson/Janssen (J&J/Janssen) | 16 | 7.2% | 11 | 6.4% |
| Moderna | 53 | 23.8% | 50 | 29.1% |
| Pfizer-BioNTech | 69 | 30.9% | 72 | 41.9% |
| Sinopharm (BIBP) | 29 | 13.0% | 12 | 7.0% |
| Sinovac (Coronavac) | 41 | 18.4% | 10 | 5.8% |
| Unvaccinated | 12 | 5.4% | 10 | 5.8% |
| Detailed primary series plus booster, No. (%) | ||||
| Covaxin plus J&J/Janssen | 0 | -- | 1 | 0.6% |
| J&J/Janssen plus Moderna | 0 | -- | 4 | 2.3% |
| J&J/Janssen plus Pfizer-BioNTech | 0 | -- | 1 | 0.6% |
| Moderna plus Moderna | 0 | -- | 12 | 7.0% |
| Moderna plus Pfizer-BioNTech | 0 | -- | 1 | 0.6% |
| Pfizer-BioNTech plus Moderna | 0 | -- | 1 | 0.6% |
| Pfizer-BioNTech plus Pfizer-BioNTech | 0 | -- | 23 | 13.4% |
| Sinopharm plus Pfizer-BioNTech | 3 | 1.3% | 4 | 2.3% |
| Sinovac plus Moderna | 0 | -- | 1 | 0.6% |
| Sinovac plus Pfizer-BioNTech | 0 | -- | 1 | 0.6% |
| Not boosted | 220 | 98.7% | 123 | 71.5% |
| Previous COVID-19 positive, No. (%) | ||||
| No | 185 | 83% | 128 | 74.4% |
| Yes, self-report | 32 | 14.3% | 37 | 21.5% |
| Yes, based on serology but not self-reportedb | 6 | 2.7% | 7 | 4.1% |
aFully vaccinated students were those with a blood draw date more than 14 days after receipt of the final COVID-19 vaccine in their primary series. Boosted students were those with a blood draw date at least 7 days after receipt of a booster dose of a COVID-19 vaccine (or any vaccine dose received after completion of a primary series). Partially vaccinated students were those with at least 1 dose of a COVID-19 vaccine who did not meet the fully vaccinated definition. Unvaccinated students were those who had not received any doses of a COVID-19 vaccine at time of blood draw. Immunocompromised status was considered when categorizing students by vaccination status.
bSera was resulted with anti-S and anti-N IgG antibody levels above the threshold of positivity (>17.66 BAU/mL and >11.8 BAU/mL, respectively) and no history of an inactivated whole virus vaccine.